HIV-2

OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

Retrieved on: 
Thursday, December 1, 2022

OraSure has played a critical role in the fight against HIV globally since 2002.

Key Points: 
  • OraSure has played a critical role in the fight against HIV globally since 2002.
  • In 2012, the Company received FDA approval for the first, and still only, over-the-counter oral fluid HIV test, the OraQuick In-Home HIV Test.
  • The OraQuick In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S.
  • The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

Retrieved on: 
Tuesday, September 20, 2022

This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.

Key Points: 
  • This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.
  • As part of the program, OraSure will provide up to one million OraQuick In-Home HIV tests over a five- year period.
  • The program will target populations that are disproportionately affected by HIV and less likely to have access to key prevention services.
  • The OraQuick In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S.

Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel

Retrieved on: 
Wednesday, June 15, 2022

HAUPPAUGE, N.Y., June 15, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq:CEMI), aleading point-of-care diagnostic company focused on infectious diseases, today announced the launch of its direct-to-consumer commercial channel for the third-party SCoV-2 Ag Detect Self-Test in the U.S. market.

Key Points: 
  • HAUPPAUGE, N.Y., June 15, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq:CEMI), aleading point-of-care diagnostic company focused on infectious diseases, today announced the launch of its direct-to-consumer commercial channel for the third-party SCoV-2 Ag Detect Self-Test in the U.S. market.
  • We are now offering the SCoV-2 Ag Detect Self-Test via our distribution network and directly through Chembio in the US.
  • In addition, we are now offering our SURE CHECK HIV Self-Test through e-commerce platforms in the UK and Brazil.
  • This commercial expansion increases our addressable market and is intended to enable deeper penetration of the market as at home testing volumes continue to grow.

OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe

Retrieved on: 
Tuesday, January 25, 2022

Were now expanding into European countries to give people there more choice and access to HIV self testing.

Key Points: 
  • Were now expanding into European countries to give people there more choice and access to HIV self testing.
  • OraQuick is the worlds first in-home oral HIV Test.
  • It is a CE-marked, pain-free HIV test that is simple to use, requiring a swipe of the upper gum and lower gum which collects HIV antibodies in oral fluid.
  • The OraQuick HIV Self-Test uses these non-infectious HIV antibodies to detect the presence of HIV.

Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark

Retrieved on: 
Wednesday, December 15, 2021

The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.

Key Points: 
  • The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.
  • Roche is pursuing CE approval for continued menu expansion on the cobas 5800 System, including cobas SARS-CoV-2, through early-to-mid 2022.
  • Roche anticipates tests to be available beyond CE markets in additional countries in 2022.
  • The cobas omni Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform.

Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark

Retrieved on: 
Wednesday, December 15, 2021

PLEASANTON, Calif., Dec. 15, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the first infectious disease tests on the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas® HIV-1, cobas® HBV, cobas® HCV, cobas® HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardised performance and efficiencies across low, medium and high volume molecular laboratory testing needs.

Key Points: 
  • PLEASANTON, Calif., Dec. 15, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit.
  • The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.
  • Roche is pursuing CE approval for continued menu expansion on the cobas 5800 System, including cobas SARS-CoV-2, through early-to-mid 2022.
  • The cobas omni Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform.

HIV-1: Global Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 8, 2021

The "Human Immunodeficiency Virus Type-1 (HIV-1) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Immunodeficiency Virus Type-1 (HIV-1) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The HIV-1 market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM HIV-1 market size from 2018 to 2030.
  • The report also covers current HIV-1 treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • These cases are expected to increase by 2030 at a CAGR of 1.26% during study period (2018-2030).

2021 Human Immunodeficiency Virus Type 1 Infection Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 17, 2021

The "Human Immunodeficiency Virus Type 1 (HIV-1) Infection - Epidemiology Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Immunodeficiency Virus Type 1 (HIV-1) Infection - Epidemiology Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • These cases are expected to increase by 2030 at a CAGR of 1.26% during study period (2018-2030).
  • Among 7MM, the United States has the highest diagnosed prevalent cases of HIV with 991,073 cases in 2020.
  • The report provides the segmentation of the disease epidemiology for 7MM total prevalent cases of HIV, total diagnosed prevalent cases of HIV, type-specific diagnosed prevalent cases of HIV, gender-specific diagnosed prevalent cases of HIV-1, diagnosed prevalent cases of HIV-1 by route of transmission, and age-specific diagnosed prevalent cases of HIV-1.